This conference, titled “The Future of Pharma R&D”, is set to address the industry's transformative challenges amid rising costs, depleted pipelines, and economic constraints, while highlighting opportunities for innovation and open-collaboration models.
This conference captures a critical moment for pharma R&D, as industry players confront mounting pressures and look toward AI, open innovation, and collaborative pipelines to sustain innovation. By assembling experts across sectors and geographies, the event aims to explore strategic pivots—from digital drug discovery to new financing models—to reinvigorate global pharmaceutical research and development.
Participants can expect deep dives into use cases, policy implications, and patient-centric approaches shaping the future of drug discovery and translational medicine.
Key Themes
Industry Pressures & Evolving R&D Models: Focuses on how high development costs, low pipeline productivity, and economic constraints are pushing pharma firms toward new collaborative and open-innovation frameworks.
Drug Discovery & Development: Sessions examining AI, machine learning, and new models for speeding drug discovery, development, and trial design.
Cross-Sector Collaboration: Emphasis on partnerships between pharmaceutical companies, biotech startups, academic institutions, CROs, and public agencies
